Saturday 17 October 2026
Export PHIO’s income statement to Excel — free account
Phio Pharmaceuticals Corp.
PHIO Healthcare Biotechnology
In the quarter to June 2026, EPS grew 20.0% and free cash flow fell 58.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.87
0.06
−6.45%
Follow PHIO
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 3 | 4 | 1 | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
P/S ratio |
63.83 | 195.04 | 17.05 | 32.12 | — | — | — | — | — | — |
Altman Z-Score |
(7.18) | (34.20) | (7.57) | (18.25) | — | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(10.95) | (82.19) | (7.59) | (38.91) | — | — | — | — | — | — |
P/Operating CF |
(3.12) | (5.94) | (1.35) | (1.72) | — | — | — | — | — | — |
P/B ratio |
0.58 | 7.13 | 0.17 | 0.76 | — | — | — | — | — | — |
Price to Tangible BV |
0.58 | 7.13 | 0.17 | 0.76 | — | — | — | — | — | — |
EV/Sales |
(129.54) | 140.85 | (91.14) | (16.22) | — | — | — | — | — | — |
EV/EBITDA |
0.97 | 0.00 | 1.73 | 0.25 | — | — | — | — | — | — |
EV/Operating CF |
1.12 | (0.99) | 1.67 | 0.26 | — | — | — | — | — | — |
EV/FCF |
1.12 | (0.97) | 1.63 | 0.25 | — | — | — | — | — | — |
Quick Ratio |
5.10 | 1.60 | 8.56 | 3.71 | 6.51 | 7.86 | 6.10 | 5.20 | 5.30 | 15.69 |
Current Ratio |
5.16 | 1.69 | 8.69 | 3.88 | 6.91 | 8.06 | 6.42 | 5.71 | 5.65 | 16.03 |
Net Debt/EBITDA |
1.45 | 0.26 | 2.05 | 0.74 | 1.61 | 1.79 | 1.04 | 0.79 | 0.73 | 2.28 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 5.11% | 1.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.07 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.70 | 0.76 | 1.02 | 0.97 | 1.00 | 0.89 | 1.06 | 0.99 | 0.99 | 0.92 |
Capex/Depreciation |
(0.08) | (2.90) | (0.06) | (1.07) | (0.26) | (0.68) | (1.70) | (0.09) | 4.00 | (4.00) |
| (136.49%) | (271.79%) | (95.52%) | (92.19%) | (93.73%) | (76.04%) | (70.06%) | (116.61%) | (114.83%) | (69.95%) | |
| (90.15%) | (142.35%) | (75.80%) | (76.26%) | (73.97%) | (64.96%) | (60.45%) | (97.63%) | (94.69%) | (63.90%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(103.66%) | (686.06%) | (54.21%) | (158.22%) | (67.00%) | (60.97%) | (107.39%) | (140.71%) | (151.39%) | (43.17%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Research and Development Expense of Revenue |
28,500.00% | 67,106.67% | 3,134.78% | 20,476.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
19,047.37% | 26,740.00% | 2,301.45% | 22,419.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
3,978.95% | 2,093.33% | 204.35% | 1,428.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
2.47 | 0.12 | 5.70 | 1.15 | — | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Earnings Yield |
(224.89%) | (104.31%) | (545.18%) | (201.86%) | — | — | — | — | — | — |
Free Cash Flow Yield |
(181.96%) | (74.36%) | (328.45%) | (199.58%) | — | — | — | — | — | — |
Revenue per Share |
190.00 | 37.50 | 115.00 | 4.88 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(77,600.00) | (23,785.00) | (6,266.67) | (2,010.47) | (207.11) | (99.81) | (96.03) | (46.33) | (9.04) | (1.33) |
Capex per Share |
(40.00) | (507.50) | (4.17) | (16.74) | (0.45) | (0.43) | (0.96) | (0.02) | 0.01 | 0.00 |
Free Cash Flow per Share |
(77,640.00) | (24,292.50) | (6,270.83) | (2,027.21) | (207.55) | (100.24) | (96.99) | (46.35) | (9.03) | (1.34) |
Cash per Share |
129,560.00 | 9,077.50 | 12,440.83 | 1,624.19 | 336.33 | 202.92 | 93.67 | 36.59 | 6.84 | 3.51 |
Shareholders Equity per Share |
108,550.00 | 4,582.50 | 11,315.00 | 1,336.74 | 306.28 | 184.61 | 85.81 | 33.32 | 6.00 | 3.37 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
108,550.00 | 4,582.50 | 11,315.00 | 1,336.74 | 306.28 | 184.61 | 85.81 | 33.32 | 6.00 | 3.37 |
Free Cash Flow |
(7.76) | (9.72) | (7.52) | (8.72) | (8.82) | (11.91) | (12.25) | (10.75) | (7.10) | (7.99) |
Working Capital |
10.56 | 1.57 | 13.41 | 5.42 | 12.97 | 21.66 | 10.51 | 7.69 | 4.72 | 20.14 |
Capital Expenditures |
0.00 | (0.20) | 0.00 | (0.07) | (0.02) | (0.05) | (0.12) | 0.00 | 0.01 | (0.01) |
Net Current Asset Value |
10.56 | 1.57 | 13.41 | 5.01 | 12.44 | 21.49 | 10.47 | 7.69 | 4.72 | 20.14 |
EV/EBIT |
0.96 | 0.00 | 1.71 | 0.25 | — | — | — | — | — | — |
Capex to Sales |
0.21 | 13.53 | 0.04 | 3.43 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.46 | 0.28 | 0.47 | 0.32 | 0.46 | 0.56 | 0.39 | 9.33 | 1.00 | 0.27 |
Cash ROIC |
(32.61%) | (177.84%) | (26.40%) | (66.32%) | (32.03%) | (25.87%) | (54.04%) | (66.30%) | (70.30%) | (19.41%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Payables |
1.04 | 0.71 | 0.53 | 0.68 | 0.77 | 0.51 | 0.53 | 0.72 | 0.46 | 0.34 |
Average Assets |
12.28 | 8.75 | 9.71 | 11.68 | 11.89 | 20.45 | 18.99 | 11.09 | 7.55 | 13.61 |
Average Common Equity |
8.11 | 4.58 | 7.71 | 9.66 | 9.38 | 17.47 | 16.39 | 9.28 | 6.23 | 12.44 |
Columns are period end dates